Not All VMAT2s Are the Same: Understanding the PK/PD Differences
from CME
Faculty: Tracy Hicks, DNP, MBA Faculty: Melissa Moody, MD Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
Embed this episode
No transcript yet.